Premium
Accurate and cost‐effective prediction of HBsAg titer in industrial scale fermentation process of recombinant Pichia pastoris by using neural network based soft sensor
Author(s) -
Hosseini Seyed Nezamedin,
Javidanbardan Amin,
Khatami Maryam
Publication year - 2019
Publication title -
biotechnology and applied biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 70
eISSN - 1470-8744
pISSN - 0885-4513
DOI - 10.1002/bab.1785
Subject(s) - pichia pastoris , hbsag , fermentation , artificial neural network , titer , bioprocess , computer science , mathematics , recombinant dna , biology , artificial intelligence , food science , hepatitis b virus , biochemistry , virology , paleontology , virus , gene
In the current work, the attempt was made to apply best‐fitted artificial neural network (ANN) architecture and the respective training process for predicting final titer of hepatitis B surface antigen (HBsAg), produced intracellularly by recombinant Pichia pastoris Mut + in the commercial scale. For this purpose, in large‐scale fed‐batch fermentation, using methanol for HBsAg induction and cell growth, three parameters of average specific growth rate, biomass yield, and dry biomass concentration—in the definite integral form with respect to fermentation time—were selected as input vectors; the final concentration of HBsAg was selected for the ANN output. Used dataset consists of 38 runs from previous batches; feed‐forward ANN 3:5:1 with training algorithm of backpropagation based on a Bayesian regularization was trained and tested with a high degree of accuracy. Implementing the verified ANN for predicting the HBsAg titer of the five new fermentation runs, excluded from the dataset, in the full‐scale production, the coefficient of regression and root‐mean‐square error were found to be 0.969299 and 2.716774, respectively. These results suggest that this verified soft sensor could be an excellent alternative for the current relatively expensive and time‐intensive analytical techniques such as enzyme‐linked immunosorbent assay in the biopharmaceutical industry.